Authors
Evidence is presented for the existence of a new C-23 oxidation pathway for the metabolism of the hormonally active form of vitamin D3, namely 1 alpha,25-dihydroxyvitamin D3 (1,25(OH)2D3). Homogenates of intestinal mucosa or kidney, but not liver, from rats and chicks convert 1,25(OH)2[26,27-3H]D3 into two new metabolites, 1 alpha,25-dihydroxy-23-oxo-vitamin D3 (1,25(OH)2-23-oxo-D3) and 1 alpha,25,26-trihydroxy-23-oxo-vitamin D3 (1,25,26(OH)3-23-oxo-D3), and an unknown metabolite(s) which has been possibly subjected to side chain modification/cleavage so that the tritium of the substrate has been converted into a form which is volatile. The isolation and chemical characterization of 1,25(OH)2-23-oxo-D3 and 1,25,26(OH)3-23-oxo-D3 from homogenates of chick intestinal mucosa has recently been described (Ohnuma, N., Kruse, J., Popjak, G., and Norman, A. W. (1982) J. Biol. Chem. 257, 5097-5102). Based on kinetic studies with chick intestinal homogenates, the proposed C-23 oxidation pathway is: 1,25(OH)2D3 leads to 1,25(OH)2-23-oxo-D3 leads to 1,25,26(OH)3-23-oxo-D3 leads to unknown metabolite with altered side chain. The relative enzyme activities of the C-23 pathway in tissues from vitamin D-replete chicks are: intestine, kidney liver, 18:3:less than 1. The activity of the C-23 pathway in homogenates of chick intestinal mucosa can be enhanced 10 x by prior priming of the birds with a single intravenous dose of 500 ng (1.3 nmol) of 1,25(OH)2D3; the induction of the enzyme activity is maximal by 3-6 h and returns to basal levels by 12 h. A comparison was made in chick and rat intestinal homogenates of this C-23 pathway and the previously known C-24 oxidation pathway, which converts 1,25(OH)2D3 into 1,24,25-trihydroxyvitamin D3 (1,24,25(OH)3D3); it was calculated that under these conditions 72% of the 1,25(OH)2D3 was metabolized by the C-23 oxidation pathway, 13% by the C-24 pathway, and only 14% by other as yet unspecified pathways. It is proposed that the newly discovered C-23 pathway for metabolism of 1,25(OH)2D3 by the target intestinal mucosa and kidney may play a prominent role under physiological conditions of controlling the tissue levels of this hormonally active form of vitamin D3.
No takes yet. Share an insight, caveat, or question.
Ohnuma et al. (1982) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: